FDA Ruling Elevates Johnson and Johnsons Tremfya in Psoriatic Arthritis
Johnson & Johnson (NYSE: JNJ) has received FDA approval for a label expansion for TREMFYA (guselkumab), confirming it as the only IL‑23 inhibitor proven to help stop further joint damage and improve symptoms in adults with active psoriatic arthritis. This updated labeling underscores TREMFYA’s positioning as a long‑term, disease‑modifying biologic therapy rather than a treatment focused solely on symptom control in PsA.
FDA label expansion for TREMFYA
The FDA has approved an update to the TREMFYA prescribing information to include data showing inhibition of structural joint damage progression in adults with active psoriatic arthritis. This update is based on 24‑week results from the Phase 3b APEX study, which demonstrated both improvement in joint symptoms (ACR20) and significantly less radiographic progression versus placebo in bio‑naïve patients.
Only IL‑23 inhibitor with joint‑damage data
With this decision, TREMFYA becomes the first and only IL‑23 inhibitor proven to provide symptom control and significantly inhibit structural joint damage progression in PsA. That differentiates it from other IL‑23 agents that have symptom data but lack comparable radiographic evidence in psoriatic arthritis.
How this fits TREMFYA’s broader label
TREMFYA is already approved in the U.S. for adults with: moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active ulcerative colitis, and moderately to severely active Crohn’s disease. It is a fully human, dual‑acting monoclonal antibody that blocks IL‑23 and also binds CD64 on IL‑23–producing cells, which Johnson & Johnson highlights as a differentiating mechanism.
